Search

Your search keyword '"Biaduzzini, Francesco"' showing total 8 results
Start Over Author "Biaduzzini, Francesco"
8 results on '"Biaduzzini, Francesco"'

2. Effects of Anti-CGRP Monoclonal Antibodies on Neurophysiological and Clinical Outcomes: A Combined Transcranial Magnetic Stimulation and Algometer Study.

Author

Manganotti, Paolo, Deodato, Manuela, D'Acunto, Laura, Biaduzzini, Francesco, Garascia, Gabriele, and Granato, Antonio

Subjects
TRANSCRANIAL magnetic stimulation, PAIN threshold, PAIN measurement, MOTOR cortex, MONOCLONAL antibodies
Abstract

Background: the aim of this study was to investigate the neurophysiological effect of anti-CGRP monoclonal antibodies on central and peripheral levels in migraine patients. Methods: An observational cohort study in patients with migraine was performed. All subjects underwent Single-Pulse and Paired-Pulse Transcranial Magnetic Stimulation, as well as a Pressure Pain Threshold assessment. The same protocol was repeated three and four months after the first injection of anti-CGRP monoclonal antibodies. Results: A total of 11 patients with a diagnosis of migraine and 11 healthy controls were enrolled. The main findings of this study are the significant effects of anti-CGRP mAb treatment on the TMS parameters of intracortical inhibition and the rise in the resting motor threshold in our group of patients affected by resistant migraine. The clinical effect of therapy on migraine is associated with the increase in short-interval intracortical inhibition (SICI), resting motor threshold (RMT), and Pressure Pain Threshold (PPT). In all patients, all clinical headache parameters improved significantly 3 months after the first injection of mAbs and the improvement was maintained at the 1-month follow-up. At baseline, migraineurs and HCs had significant differences in all TMS parameters and in PPT, while at follow-up assessment, no differences were observed on RMT, SICI, and PPT between the two groups. After anti-CGRP monoclonal antibody injection, a significant increase in the intracortical inhibition, in the motor threshold, and in the Pressure Pain Threshold in critical head areas was observed in patients with migraine, which was related to significant clinical benefits. Conclusions: Anti-CGRP monoclonal antibodies improved clinical and neurophysiological outcomes, reflecting a normalization of cortical excitability and peripheral and central sensitization. By directly acting on the thalamus or hypothalamus and indirectly on the trigeminocervical complex, treatment with anti-CGRP monoclonal antibodies may modulate central sensorimotor excitability and peripheral sensitization pain. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Cognitive deficit in post-acute COVID-19: an opportunity for EEG evaluation?

Author

Giovanni Furlanis, Alex Buoite Stella, Francesco Biaduzzini, Giulia Bellavita, Nicolò Arjuna Frezza, Sasha Olivo, Alina Menichelli, Alberta Lunardelli, Miloš Ajčević, Paolo Manganotti, Furlanis, Giovanni, Buoite Stella, Alex, Biaduzzini, Francesco, Bellavita, Giulia, Frezza, Nicolò Arjuna, Olivo, Sasha, Menichelli, Alina, Lunardelli, Alberta, Ajcevic, M, and Manganotti, Paolo

Subjects
Psychiatry and Mental health, Cognitive impairment, Post-COVID-19, COVID-19, EEG, Neurology (clinical), Dermatology, General Medicine
Abstract

Background and purpose: Among the most common post-COVID symptoms, many patients experienced subjective cognitive deficit, commonly named "brain fog," that might be present also in those individuals without severe acute COVID-19 respiratory involvement. Some studies have investigated some of the mechanisms that might be associated with the brain fog with objective techniques including transcranial magnetic stimulation and neuroimaging. Methods: The aim of this study was to investigate the presence of electroencephalographic (EEG) alterations in people with post-COVID self-reported cognitive deficit. Results: Out of the 90 patients attending the post-COVID neurology ambulatory service, twenty patients presenting brain fog at least 4 weeks after acute non-severe COVID-19 infection, and without previous history of epilepsy, were investigated with 19-channel EEG, Montreal Cognitive Assessment (MoCA), and magnetic resonance imaging (MRI). EEG was found altered in 65% of the sample, among which 69% presented a slowing activity and 31% were characterized by epileptic discharges principally in the frontal areas. None of the patients showed DWI MRI lesions. Conclusions: These findings highlight the usefulness of EEG analysis to objectively describe possible neurophysiological abnormalities in post-COVID patients presenting subjective cognitive deficit.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results